Femasys(FEMY)

SUWANEE, GABiotechnology1 H-1B visas (FY2023)

Focus: Femasys is a publicly traded women's health biotech focused on developing medical devices and technologies for contraception, fertility, and diagnostic applications. The company is in early commercialization stage with minimal revenue generation.

Women's Health

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Femasys

AI assessmentNot Hiring

No open roles listed right now. Follow Femasys to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$2M

FY2025

Key Products

FemaSeed Localized Directional Insemination

Infertility

Growth

Early-stage fertility device addressing infertility market; 1 active trial.

FemBloc Permanent Contraceptive System

Contraception

Help build intelligence for Femasys

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage public company in women's health, a historically underserved and high-growth therapeutic area
Portfolio spans multiple market segments (contraception, infertility, diagnostics) providing diverse career exposure
Perfect.com entry point if seeking ground-floor equity upside in a focused biotech with public market validation

Watch Out For

Severe cash burn: $14–19M annual net losses against only $1–2M revenue; cash runway concerns despite $3M current position
No active job openings reported; extremely small team with no hiring momentum and limited career mobility
Unproven commercial execution; all pipeline programs are early-stage devices with no traditional drug development phase data

Generated by Claude from Femasys's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Lead contraceptive device program; multiple trial registrations indicate active development.

FemVue

Fallopian Tube Patency Tests

Growth

Diagnostic tool for assessing fallopian tube patency; 1 active trial.

Pipeline & Clinical Trials

FemBloc

Contraception

N/A

Clinical Trials (1)

NCT03433911FemBloc® Permanent Contraception - Early Pivotal Trial

N/A

FemBloc® Permanent Contraceptive System

Contraception

N/A

Clinical Trials (1)

NCT03067272Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

N/A

Sonography with FemVue, and HSG

Fallopian Tube Patency Tests

N/A

Clinical Trials (1)

NCT01053052Study of FemVue(TM) Sono Tubal Evaluation System Method Comparison to HSG

N/A

FemBloc

Contraception

N/A

Clinical Trials (1)

NCT05977751Prospective Multi-Center Trial for FemBloc Permanent Birth Control

N/A

FemBloc

Contraception

N/A

Clinical Trials (1)

NCT04273594FemBloc® Permanent Contraception - Confirmation Feasibility Trial

N/A

FemaSeed Localized Directional Insemination

Infertility

N/A

Clinical Trials (1)

NCT04968847FemaSeed LOCAL Artificial Insemination Trial

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 6 clinical trials

H-1B (2023): 1 approval

SEC Filings: 2 available

Financials (FY2025)

Revenue

$2M52%

R&D Spend

$8M(504%)14%

Net Income

-$19M

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo